Advancing HetSiFA® radiotheranostics
Fuzionaire Theranostics’ pipeline combines scalable PET imaging with radioligand therapy.
We develop complementary radiopharmaceutical pairs that connect fluorine-18 PET imaging with therapeutic radiometal delivery. Our HetSiFA® platform enables diagnostic and therapeutic agents to be designed from chemically matched molecular scaffolds. Our lead therapeutic focus is lutetium-177, with selective exploration of terbium-161 and lead-212 where justified by target biology.
Exploration
Discovery
Lead Optimization
First-in-Human
FTX-426 lead program (target GRPR)
Exploration
Discovery
Lead Optimization
First-In-Human
18F/
177Lu theranostic pair
FTX-426 is a GRPR-targeted HetSiFA®-DOTA radioligand designed to enable a chemically matched fluorine-18/lutetium-177 theranostic pair. Preclinical work supports receptor-specific tumor targeting and robust radiochemistry, with first-in-human therapeutic
feasibility supporting continued clinical translation. FTX-426 is being developed for GRPR-expressing solid tumors, including prostate and breast cancer. Prospective fluorine-18 imaging and dosimetry studies are planned to support patient
selection, biodistribution assessment, and therapy development.
Undisclosed oncology program (target undisclosed)
Exploration
Discovery
Lead Optimization
First-In-Human
18F/
161Tb
theranostic pair
theranostic pair
An undisclosed oncology program is evaluating where matched fluorine-18 PET and terbium-161 radioligand therapy may be suited for lower-volume or micrometastatic disease. The rationale is to combine matched molecular design with terbium-161’s beta emission
and short-range conversion/Auger electrons, potentially supporting development in settings where microscopic disease control is central to the therapeutic strategy.
Undisclosed oncology program (target undisclosed)
Exploration
Discovery
Lead Optimization
First-In-Human
18F/
212Pb
theranostic pair
theranostic pair
The undisclosed oncology program explores fluorine-18 PET paired with chemically matched lead-212 radioligand therapy. The program is evaluating an indication where the
18F/
212Pb pair with more closely aligned radionuclide half-lives could meaningfully improve patient selection, dose planning, and therapeutic decisionmaking.